GAITHERSBURG, Md., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Louis J. Aronne, Founder and Director of the Center for Weight Management at Weill-Cornell Medical Center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th Annual Meeting of the European Association for the Study of Diabetes in Hamburg, Germany. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (NASH).
Details for the oral presentation are as follows:
| Title: | Phase 2, Randomized, Placebo-controlled Trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis (Session OP 10, Oral Presentation 60) |
| Presenter: | Louis J. Aronne, M.D., Founder and Director, Center for Weight Management at Weill-Cornell Medical Center |
| Date/Time: | Tuesday, October 3, 2023, at 4:30 pm CEST |
About Pemvidutide
Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, leading to rapid reductions in levels of liver fat. Pemvidutide incorporates the EuPort™ domain, a proprietary technology that increases its serum half-life for weekly dosing while likely slowing the entry of pemvidutide into the bloodstream, which may improve its tolerability.
About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation therapeutics for the treatment of patients with liver diseases and obesity. The Company’s lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Investor & Media Contacts:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.66 |
| Daily Change: | 0.35 4.79 |
| Daily Volume: | 6,572,773 |
| Market Cap: | US$544.780M |
November 12, 2024 November 07, 2024 October 15, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
